Page last updated: 2024-08-18

pyrroles and Cancer of Pancreas

pyrroles has been researched along with Cancer of Pancreas in 188 studies

Research

Studies (188)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	4 (2.13)	18.2507
2000's	29 (15.43)	29.6817
2010's	144 (76.60)	24.3611
2020's	11 (5.85)	2.80

Authors

Authors	Studies
Aoyama, Y; Hayashi, Y; Imafuji, H; Kato, T; Kimura, M; Matsuo, Y; Mitsui, A; Morimoto, M; Murase, H; Ogawa, R; Omi, K; Saito, K; Takahashi, H; Takiguchi, S; Tsuboi, K; Ueda, G	1
Mazepa, ASW; Myers-Nodes, J	1
Cheng, Y; Hu, L; Wang, S; Zhang, L; Zhao, J; Zheng, X	1
Chong, D; Gu, Y; Guan, X; Jiang, T; Lu, Z; Song, N; Wang, JY; Wang, X; Wang, Y; Yu, R; Yu, W; Zhang, S	1
Bando, T; Hashiya, K; Hirose, Y; Sato, S; Sugiyama, H	1
Dekhne, AS; Frühauf, J; Gangjee, A; Hou, Z; Hüttemann, M; Kalpage, H; Kim, S; Matherly, LH; Nayeen, MJ; Ning, C; O'Connor, C; Shah, K; Wallace-Povirk, A	1
Cheng, K; Fetse, JP; Jain, A; Li, Y; Lin, CY; Liu, H; Zhao, Z	1
Brentnall, A; Brown, NF; Delgado, BL; Desai, A; Hartley, JA; Howard, P; Marshall, JF; Masterson, L; Moore, KM; Murray, ER; Reader, C; Trabulo, SMD; van Berkel, PH; Zammarchi, F	1
Li, Y; Quan, Y; Shi, X; Wang, Y	1
Alonso-Miguel, D; Clarés Moral, I; García-San José, P; González Sanz, S; Pérez-Alenza, MD	1
Johannes, CM; Musser, ML	1
Chung, MH; Hahm, KB; Han, YM; Jeong, M; Ko, KH; Kwon, CI; Park, JM	1
Bertani, E; Bonomo, G; Cella, C; Fazio, N; Funicelli, L; Gibelli, B; Grana, C; Lambrescu, I; Martins, D; Pisa, E; Ravizza, D; Ribero, D; Rubino, M; Spada, F; Zerini, D	1
Broder, MS; Chang, E; Neary, MP; Reddy, SR	1
Bill, R; Blank, A; Krebs, P; Marinoni, I; Normand, L; Pantasis, S; Perren, A; Tschan, MP; Wiedmer, T	1
Baldwin, G; He, H; Huynh, N; Nikfarjam, M; Wang, K; Wang, X	1
Han, JJ; Kim, SY; Lee, YS; Maeng, CH	1
Avniel-Polak, S; Gross, DJ; Grozinsky-Glasberg, S; Uri, I	1
Escobar, MA; McClellan, JM; Thomas, W	1
Antonuzzo, L; Badalamenti, G; Berardi, R; Bongiovanni, A; Brighi, N; Brizzi, MP; Campana, D; Carnaghi, C; Catena, L; Delle Fave, G; Faggiano, A; Falconi, M; Fazio, N; Femia, D; Gelsomino, F; Gritti, S; Ibrahim, T; Marconcini, R; Panzuto, F; Partelli, S; Pusceddu, S; Ricci, S; Rinzivillo, M; Schinzari, G; Spada, F; Spallanzani, A	1
Dasic, G; Frajzyngier, V; Jones, T; Madsen, A; Rojo, R; Valdez, H	1
Abe, T; Hashimoto, R; Igarashi, H; Inoue, K; Ito, T; Karashima, T; Kawabe, K; Miki, M; Ogawa, Y; Ohishi, Y; Yamasaki, I	1
Debbagh, A; Errihani, H; Ichou, M; Mahi, M; Sbitti, Y; Slimani, K	1
Akahoshi, K; Akashi, T; Ban, D; Kudo, A; Mitsunori, Y; Mizuno, Y; Ogawa, K; Ogura, T; Ono, H; Tanabe, M; Tanaka, S; Tateishi, U	1
Hou, XF; Li, K; Li, S; Wang, JF; Wu, C; Xu, SN	1
Aubé, J; Baserga, SJ; Bian, Y; Chen, W; Chow, E; Dextras, C; Fang, M; Farley, KI; Feldman, C; Ferrer, M; Frankowski, KJ; Goldberg, E; Griner, LM; Hu, D; Huang, H; Huang, S; Kandela, I; Kang, J; Khanolkar, O; Kim, HR; Knotts, Z; Kozlov, S; Lewandowska, MA; Li, D; Long, C; Marugan, JJ; Mazar, A; Meng, Z; Nagashima, K; Norton, J; Patnaik, S; Powers, AS; Quadri, HS; Rudloff, U; Sahagian, G; Schoenen, FJ; Shilatifard, A; Southall, N; Sultan, J; Sun, W; Teper, Y; Titus, S; Vilimas, T; Wang, C; Wen, Y; Xi, R; Zheng, W; Zhou, M	1
Andersen, LMK; Gaustad, JV; Hauge, A; Rofstad, EK; Simonsen, TG; Wegner, CS	1
Boudreaux, BB; Dedeaux, AM; Langohr, IM	1
Akimoto, Y; Ikehara, S; Ikehara, Y; Kume, M; Nakanishi, H; Ohara, O; Yamaguchi, T; Yamamoto, K	1
Bourcier, ME; Vinik, AI	1
Bravo, J; Cañueto, J; de Unamuno, P; Mir-Bonafé, JM	1
Mankal, P; O'Reilly, E	1
Libutti, SK; Saif, MW; Stevenson, R	1
Christensen, JG; Ishiguro-Oonuma, T; McDonald, DM; Schriver, BJ; Sennino, B	1
Chiu, WY; Hung, IF; Mok, MY; Shea, YF; Yau, CC	1
Bisht, S; Brossart, P; Feldmann, G	1
Chen, HR; Li, P; Lin, LZ; Pang, LJ	1
Bansal, SS; Celia, C; Ferrari, M; Ferrati, S; Grattoni, A; Palapattu, G; Zabre, E	1
Francois, R; Hochwald, SN; Iyer, R; Seshadri, M; Zajac-Kaye, M; Zhang, J	1
Khagi, S; Saif, MW	1
Saif, MW; Sarris, EG; Syrigos, KN	1
Aprile, G; Belli, C; Bergamo, F; Ceraulo, D; Cereda, S; Danova, M; Di Lucca, G; Franceschi, E; Fugazza, C; Mambrini, A; Milella, M; Novarino, A; Passardi, A; Reni, M; Villa, E	1
Bonkovsky, HL; Hwang, SI; Lee, JG; McKinney, KQ; Mougeot, JL	1
Baudin, E; Borson-Chazot, F; Hescot, S; Lombès, M	1
Castellano, D; Faivre, S; González, E; Salazar, R; Strosberg, J	1
Anjali, CH; George, PD; Rajith, B; Ravindran, A; Sripriyalakshmi, S	1
Chen, S; Ge, Y; Niu, X; Tan, W; Wang, G; Wang, H; Zhao, J; Zhao, L	1
Faivre, S; Ishak, KJ; Korytowsky, B; Proskorovsky, I; Sandin, R; Valle, J	1
Conney, AH; Cui, XX; Ding, N; Du, Z; Gao, Z; Hu, C; Huang, H; Lin, Y; Rabson, AB; Shih, WJ; Wei, X; Zheng, X	1
Amiel, SA; Aylwin, SJ; Huda, MS; Ross, P	1
Cho, Y; Je, DW; Ji, YG; Lee, DH; O, YM	1
Baxter, RC; Gill, AJ; Hugh, TJ; Julovi, SM; Pavlakis, N; Peters, L; Samra, JS; Smith, RC; Wong, MH; Xue, A	1
Jiang, CY; Wang, HW; Wang, W	1
Faneca, H; Passadouro, M; Pedroso de Lima, MC	1
Karampelas, IN; Saif, MW; Syrigos, KN	1
Faivre, S; Grande, E; Hubner, RA; Raymond, E; Valle, JW	1
Brixi, H; Cadiot, G; de Mestier, L; Lombard-Bohas, C; Walter, T	1
Chen, S; Cui, L; Cui, X; Edwards, H; Ge, Y; Wang, G	1
Bareggi, C; Dell'orto, PG; Galassi, B; Gambini, D; Gianelli, U; Locatelli, E; Massironi, S; Tomirotti, M; Visintin, R	1
Boratyn-Nowicka, A; Ćwikła, JB; Jarząb, B; Kos-Kudła, B; Michalik, B; Nawrocki, S; Piątek, M; Rogowski, W; Szabłowska-Siwik, S; Wachuła, E; Zemczak, A	1
Takahashi, M	1
Kulke, MH	2
Brewer, M; Cruz-Monserrate, Z; Houchen, CW; Janakiram, NB; Kumar, G; Lightfoot, S; Madka, V; May, R; Mohammed, A; Patlolla, JM; Rao, CV; Ritchie, RL; Sadeghi, M; Steele, VE; Yamada, HY	1
Cottle-Delisle, C; Kebebew, E; Marx, S; Meltzer, P; Merkel, R; Neychev, V; Nilubol, N; Pacak, K; Steinberg, SM; Yao, J	1
Atkinson, BJ; Corn, PG; Jonasch, E; Kalra, S; Karam, JA; Matin, SF; Matrana, MR; Rao, P; Sircar, K; Tamboli, P; Tannir, NM; Wood, CG	1
Grandhi, MS; Lafaro, KJ; Pawlik, TM	1
Biddick, L; Brewer, M; Devarkonda, V; Janakiram, NB; Lightfoot, S; Madka, V; Mohammed, A; Rao, CV; Steele, VE	1
Kunz, PL; Phan, AT; Reidy-Lagunes, DL	1
Abe, H; Hirano, S; Hiraoka, K; Hontani, K; Inoko, K; Kushibiki, T; Nakamura, T; Nishihara, H; Sato, N; Sato, S; Shichinohe, T; Takahashi, M; Takano, H; Takeuchi, S; Tsuchikawa, T	1
Gardner, EE; Rudin, CM	1
Huggett, MT; Keane, MG; Loddo, M; Pereira, SP; Proctor, I; Stoeber, K; Tudzarova, S; Williams, GH	1
Akiyama, S; Fujishima, F; Imai, H; Ishioka, C; Kobayashi, A; Komine, K; Saijo, K; Sato, N; Shimodaira, H; Shirota, H; Shuin, T; Sugiyama, S; Takahashi, M; Takahashi, S	1
Führer, D; Kühl, H; Lahner, H; Lehmann, N; Poeppel, TD; Rinke, A; Unger, N	1
Allen, E; Hanahan, D; Li, L; Miéville, P; Peng, MW; Saghafinia, S; Warren, CM	1
Anta, H; Fillat, C; Gibert, J; Guerrero, PE; Iglesias, M; José, A; Martínez-Bosch, N; Moreno, M; Munné-Collado, J; Navarro, P; Orozco, CA; Vinaixa, J; Viñals, F	1
Meng, CT; Ying, HY	1
Askin, G; Buchy, E; Cayre, F; Couvreur, P; Desmaele, D; Gouazou, S; Mougin, J; Mura, S; Sobot, D; Stella, B; Valetti, S	1
Aitali, A; Albouzidi, A; Benani, F; Debbagh, A; Errihani, H; Ichou, M; Mahi, M; Sbitti, Y; Seddik, H; Slimani, K; Tarchouli, M	1
Howe, JR; Maxwell, JE; Sherman, SK	1
Capozzi, M; DE Divitiis, C; Ottaiano, A; Romano, GM; Tafuto, S; Tatangelo, F; VON Arx, C	1
Bang, YJ; Borbath, I; Castellano, D; Chen, JS; Faivre, S; Hammel, P; Ishak, KJ; Lee, SH; Lombard-Bohas, C; Lu, DR; Metrakos, P; Niccoli, P; Patyna, S; Raoul, JL; Raymond, E; Ruszniewski, P; Seitz, JF; Smith, D; Valle, JW; Van Cutsem, E; Vinik, A	1
Gilabert, M; Kavan, P; Rho, YS	1
Bang, YJ; Bottomley, A; Chao, RC; Hörsch, D; Korytowsky, B; Metrakos, P; Mundayat, R; Raoul, JL; Raymond, E; Reisman, A; Valle, JW; Vinik, A; Wang, Z	1
Chae, H; Chang, HM; Cho, H; Hong, SM; Hong, YS; Kang, YK; Kim, KP; Kim, SC; Kim, TW; Ryoo, BY; Ryu, MH; Song, MJ; Yoo, C	1
Adham, M; Forestier, J; Foulfoin, M; Graillot, E; Hervieu, V; Lombard-Bohas, C; Robinson, P; Rousset, P; Scoazec, JY; Walter, T	1
Angelousi, A; de Herder, W; Kaltsas, G; Kaltsatou, M; Kamp, K; O'Toole, D	1
Chen, J; Chen, M; Feng, ST; Huang, K; Li, ZP; Lin, Y; Luo, Y; Xu, L	1
Chakravarthy, AB; Cuneo, KC; Fu, A; Geng, L; Hallahan, DE; Orton, D	1
Akamatsu, S; Kanamaru, S; Soeda, A; Takenawa, J	1
Baum, CM; Bergsland, E; Fuchs, CS; Huang, X; Kulke, MH; Lenz, HJ; Li, JZ; Meropol, NJ; Picus, J; Posey, J; Ryan, DP; Stuart, K; Tye, L	1
Cusack, JC; Houston, M; Liu, R; Ljungman, D; Palladino, MA; Sloss, CM; Wang, F; Xia, L	1
Huang, S; Okumura, K; Sinicrope, FA	1
Andrieu, JM; Azizi, M; Banu, E; Chedid, A; Fournier, L; Helley, D; Medioni, J; Mejean, A; Oudard, S; Scotte, F	1
Carrier, MK; Gunasekera, SP; Guzmán, EA; Johnson, JD; Meyer, CI; Pitts, TP; Wright, AE	1
Chan, JA; Kulke, MH	1
Cho, D; Choueiri, TK; Fournier, L; Medioni, J; Oudard, S; Zinzindohoué, F	1
Boterberg, T; Casneuf, VF; Delrue, L; Demetter, P; Peeters, M; Van Damme, N	1
Mistafa, O; Stenius, U	1
Bharthuar, A; Iyer, R; Kuvshinoff, B; LeVea, C; Litwin, A; Pearce, L	1
Chun, MG; Golub, TR; Hanahan, D; Libutti, SK; Lu, J; Nakakura, EK; Olson, P; Shai, A; Wang, Y; Zhang, H	1
Faivre, S; Hammel, P; Raymond, E; Ruszniewski, P	1
Wang, ZY	1
Dimou, AT; Saif, MW; Syrigos, KN	1
Beck, J; Bellmunt, J; Escudier, B	1
Bouvet, M; Fruehauf, J; Hoffman, RM; Imagawa, DK; Katz, MH; Kaushal, S; Keleman, A; Kim, G; Romney, E; Tran Cao, HS	1
Audrain, O; Boucher, E; Leroux, C; Picot, D; Raoul, JL; Zoheir, Y	1
Bodei, L; Cinieri, S; de Braud, F; Delle Fave, G; Fazio, N; Lorizzo, K; Maiello, E; Orlando, L; Paganelli, G; Spada, F; Squadroni, M	1
Abou-Alfa, GK; Bekaii-Saab, T; Douglas, K; Goldberg, RM; Hall, M; Hollis, D; Kindler, HL; Niedzwiecki, D; O'Reilly, EM; Pluard, T; Schilsky, RL	1
Bang, YJ; Blanckmeister, C; Borbath, I; Chao, R; Chen, JS; Dahan, L; Hammel, P; Hörsch, D; Lombard-Bohas, C; Lu, DR; Metrakos, P; Patyna, S; Raoul, JL; Raymond, E; Ruszniewski, P; Smith, D; Valle, J; Van Cutsem, E; Vinik, A; Wiedenmann, B	1
Delle Fave, G; Jensen, RT	1
Angeles Vaz, M; Carrato, A; García de Paredes, ML; Grande, E; Guillén, C; José Díez, J; Longo, F; Pachón, V	1
Saif, MW; Strimpakos, AS; Syrigos, KN	2
Hanahan, D; Tuveson, D	1
Libutti, SK; Spiegel, AM	1
Peres, J	1
Kleijn, SA; van der Veldt, AA	1
Barriuso, J; Castellano, D; Grande, E	1
Berruti, A; Pia, A; Terzolo, M	1
Coriat, R; Goldwasser, F; Mir, O	1
de Herder, WW; Feelders, RA; Kwekkeboom, D; van Schaik, E	1
Awasthi, N; Schwarz, MA; Schwarz, RE	1
Yim, KL	1
Bazan, F; Bouchet, S; Curtit, E; Kalbacher, E; Maurina, T; Montange, D; Nguyen, T; Pivot, X; Royer, B; Thiery-Vuillemin, A	1
Baltogiannis, G; Katsios, C; Roukos, DH	1
Liakakos, T; Roukos, DH	1
Deeks, ED; Raymond, E	1
Cabral, H; Chen, Q; Kano, MR; Kataoka, K; Kimura, M; Matsumoto, Y; Miyazono, K; Mizuno, K; Murakami, M; Nishiyama, N; Terada, Y; Uesaka, M	1
Drabkin, HA; Gemmill, RM; Lay, A; Lee, L; Lloyd, GK; Longenecker, A; McConkey, DJ; Millward, M; Neuteboom, ST; Palladino, MA; Price, T; Sharma, G; Spear, MA; Spencer, A; Sukumaran, S; Sweeney, C; Townsend, A	1
Chu, GC; Hanahan, D; Nolan-Stevaux, O; Olson, P; Perry, SR	1
Davis, DW; Fuller, GN; Gombos, DS; Jonasch, E; Matin, SF; McCutcheon, IE; Smith, LA; Tannir, NM; Waguespack, SG; Wen, S	1
Hubner, RA; Valle, JW	1
Amano, R; Doi, Y; Hirakawa, K; Noda, S; Yamada, N; Yashiro, M	1
Janakiram, NB; Lightfoot, S; Mohammed, A; Qian, L; Rao, CV; Steele, VE	1
Bellail, AC; Ding, L; Hao, C; Liu, Y; Lu, G; Olson, JJ; Sun, SY; Wang, G; Wei, F; Yuan, C	1
Fu, J; Shankar, S; Srivastava, RK; Tang, SN	1
Gao, F; Sita-Lumsden, A; Visvardis, EE; Waxman, J	1
Reidy-Lagunes, D; Thornton, R	1
Bussolino, F; Capano, S; Casanovas, O; Giacca, M; Giraudo, E; Maione, F; Regano, D; Serini, G; Zentilin, L	1
Heymach, JV; Mateo, J; Zurita, AJ	1
Chung, YT; Li, H; Liao, J; Yan, L; Yang, AL; Yang, GY; Zhang, M; Zhang, W	1
Caviezel, C; Christofori, G; García-Echeverría, C; Hofmann, F; Pisarsky, L; Strittmatter, K; Zumsteg, A	1
Benavent, M; de Miguel, MJ; Garcia-Carbonero, R	1
Capdevila, J; Tabernero, J	1
Arora, PS; Dervan, PB; Gottesfeld, JM; James Chou, C; Jespersen, C; Soragni, E	1
Barck, KH; Cao, TC; Carano, RA; Cheng, JH; Couto, SS; Eastham-Anderson, J; Ferrara, N; Foreman, O; Forrest, WF; Hamilton, P; Ho, CC; Johnson, L; Jubb, AM; Kasman, I; Lima, A; Long, JE; McNutt, A; Molina, R; Nannini, MA; Reslan, HB; Singh, M	1
Dreyer, C; Faivre, S; Hammel, P; Hentic, O; Maatescu, C; Raymond, E; Ruszniewski, P	1
Raymond, E; Ruszniewski, P	1
Chen, CR; Kodra, JT; Liu, X; Yu, R	1
Awasthi, N; Ruan, W; Schwarz, MA; Schwarz, RE; Zhang, C	1
Boninsegna, L; Crippa, S; Falconi, M; Partelli, S	1
Xu, JM	1
Halfdanarson, TR; Naraev, BG; Strosberg, JR	1
Murugesan, S; Nadkarni, DH; Velu, SE; Voruganti, S; Wang, MH; Wang, W; Xu, H; Zhang, R; Zhang, X	1
Braunfeld, J; Brekken, RA; Burrows, FJ; Carbon, JG; Kirane, A; Ostapoff, K; Schwarz, RE; Toombs, JE; Zaknoen, S	1
Blumenthal, GM; Cortazar, P; Justice, R; Murgo, A; Pazdur, R; Sridhara, R; Tang, S; Zhang, JJ	1
Casciano, R; Chulikavit, M; Garrison, LP; Liu, Z; Perrin, A; Wang, X	1
Dreyer, C; Faivre, S; Raymond, E	1
Couvelard, A; de Gramont, A; Faivre, S; Hammel, P; Neuzillet, C; Raymond, E; Serova, M; Tijeras-Raballand, A	1
Igarashi, H; Ito, T; Jensen, RT; Takayanagi, R	1
Baum, RP; Bert, T; Hommann, M; Hörsch, D; Kaemmerer, D; Petrovitch, A; Schrader, J; Zaknun, J	1
Chao, RC; Hara, K; Hashigaki, S; Igarashi, H; Imamura, M; Ito, T; Kimura, N; Kondo, S; Mizuno, N; Morizane, C; Murakami, M; Nishida, T; Ohki, E; Okusaka, T; Sawaki, A; Yamao, K	1
Barna, ME; Pastorello, M; Uomo, I	1
Peng, L; Schwarz, RE	1
Dalgleish, A; Ioannou, N; Mackintosh, D; Modjtahedi, H; Seddon, AM	1
Öberg, K	1
Bergers, G; Hanahan, D	1
Fidler, IJ; Yokoi, K	1
Bevilacqua, G; Bocci, G; Boggi, U; Boschi, E; Campani, D; Danesi, R; Del Tacca, M; Esposito, I; Fasciani, A; Fioravanti, A; Marangoni, G; Mosca, F	1
Hanahan, D; Pietras, K	1
Abbruzzese, JL; Davis, DW; Demetri, GD; Herbst, RS; Heymach, JV; McConkey, DJ; Rashid, A; Raut, CP; Shen, Y; Stadler, WM; Takamori, R; Wen, S; Xiong, HQ	1
Berezin, V; Billestrup, N; Bock, E; Heding, P; Li, S; Mandrup-Poulsen, T; Petersen, LG; Saldeen, J; Størling, J	1
Abbruzzese, JL; Chiao, PJ; Fleming, JB; Ishiyama, S; Melisi, D; Sclabas, GM; Tortora, G; Xia, Q	1
Gaumann, A; Geissler, EK; Lang, SA; Mori, A; Moser, C; Schachtschneider, P; Schlitt, HJ; Stoeltzing, O; Zimmermann, J	1
Edwards, G; Weston, AH	1
Ayton, BA; Dunne, MJ; Harding, EA; Jaggar, JH	1
Dan, K; Hirose, H; Maruyama, H; Nakamura, K; Saruta, T; Seto, Y	1
Fuhlendorff, J; Gromada, J; Madsen, P; Springborg, J; Varming, AR	1
Abbruzzese, J; Bruns, CJ; Buchdunger, E; Fan, D; Fidler, IJ; Harbison, MT; Ozawa, S; Radinsky, R; Solorzano, CC; Traxler, P; Tsan, R	1
Benali, N; Buscail, L; Calise, D; Cordelier, P; Esteve, JP; Nagy, A; Pages, P; Pour, PM; Rochaix, P; Schally, AV; Susini, C; Vaysse, N	1
Baker, CH; Buchdunger, E; Cohen, P; Fidler, IJ; Killion, JJ; Solorzano, CC; Traxler, P; Tsan, R	1
Csernus, B; Halmos, G; Hebert, F; Nagy, A; Schally, AV; Sun, B; Szepeshazi, K	1
Cherrington, JM; Griffin, RJ; Park, H; Song, CW; Wild, R; Williams, BW	1
Baker, CH; Fidler, IJ; Solorzano, CC	1

Reviews

34 review(s) available for pyrroles and Cancer of Pancreas

Article	Year
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. Science & sports, 2023, Apr-04 Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide	2023
Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors. Targeted oncology, 2017, Volume: 12, Issue:5 Topics: Antineoplastic Agents; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib	2017
Pneumatosis cystoides intestinalis associated with sunitinib and a literature review. BMC cancer, 2017, Nov-09, Volume: 17, Issue:1 Topics: Aged; Antineoplastic Agents; Female; Humans; Indoles; Pancreatic Neoplasms; Pneumatosis Cystoides Intestinalis; Pyrroles; Sunitinib	2017
Update in the Therapy of Advanced Neuroendocrine Tumors. Current treatment options in oncology, 2017, 11-16, Volume: 18, Issue:12 Topics: Combined Modality Therapy; Cytoreduction Surgical Procedures; Everolimus; Humans; Indoles; Intestinal Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Somatostatin; Stomach Neoplasms; Sunitinib	2017
Sunitinib malate for the treatment of pancreas malignancies--where does it fit? Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:6 Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Indoles; Neovascularization, Pathologic; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib	2013
Novel agents in gastroenteropancreatic neuroendocrine tumors. JOP : Journal of the pancreas, 2013, Mar-10, Volume: 14, Issue:2 Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Drugs, Investigational; Everolimus; Gastrointestinal Neoplasms; Humans; Indoles; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib	2013
Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors. Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Indoles; Neovascularization, Pathologic; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib	2013
Current understanding of the molecular biology of pancreatic neuroendocrine tumors. Journal of the National Cancer Institute, 2013, Jul-17, Volume: 105, Issue:14 Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Cell Hypoxia; Co-Repressor Proteins; Cyclin-Dependent Kinase Inhibitor p18; Disease Progression; Disease-Free Survival; Everolimus; Gene Knock-In Techniques; Gene Knockout Techniques; Genetic Predisposition to Disease; Humans; Indoles; Islets of Langerhans; Molecular Chaperones; Molecular Targeted Therapy; Mutation; Neovascularization, Pathologic; Neuroendocrine Tumors; Nuclear Proteins; Octreotide; Pancreatic Neoplasms; Proto-Oncogene Proteins; Pyrroles; Receptor, Notch1; Signal Transduction; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases	2013
[Targeted therapies, prognostic and predictive factors in endocrine oncology]. Annales d'endocrinologie, 2013, Volume: 74 Suppl 1 Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials, Phase III as Topic; Disease-Free Survival; Endocrine Gland Neoplasms; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperidines; Prognosis; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Outcome	2013
Pancreatic NETs: where do we stand now? Cancer metastasis reviews, 2014, Volume: 33, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib; Treatment Outcome; Tumor Suppressor Proteins	2014
Targeted agents in treatment of neuroendocrine tumors of pancreas. JOP : Journal of the pancreas, 2014, Jul-28, Volume: 15, Issue:4 Topics: Antineoplastic Agents; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib; Survival Analysis; Treatment Outcome	2014
Role of Locoregional and Systemic Approaches for the Treatment of Patients with Metastatic Neuroendocrine Tumors. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2015, Volume: 19, Issue:12 Topics: Antineoplastic Agents; Humans; Indoles; Intestinal Neoplasms; Liver Neoplasms; Liver Transplantation; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis; Pyrroles; Stomach Neoplasms; Sunitinib	2015
Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Oct-15, Volume: 22, Issue:20 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; CD47 Antigen; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Pyrroles; Sunitinib; TOR Serine-Threonine Kinases	2016
Antiangiogenic Therapy in Pancreatic Neuroendocrine Tumors. Anticancer research, 2016, Volume: 36, Issue:10 Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Humans; Indoles; Neovascularization, Pathologic; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib	2016
Progress in the treatment of neuroendocrine tumors. Current oncology reports, 2009, Volume: 11, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Combined Modality Therapy; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Pyrroles; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib	2009
[Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2009, Volume: 31, Issue:9 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Deoxycytidine; Drug Delivery Systems; Gastrointestinal Stromal Tumors; Gemcitabine; Humans; Imatinib Mesylate; Indoles; Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sunitinib	2009
Neuroendocrine tumors of the pancreas: what's new. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. JOP : Journal of the pancreas, 2010, Mar-05, Volume: 11, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Clinical Trials as Topic; Combined Modality Therapy; Congresses as Topic; Everolimus; Gastrointestinal Neoplasms; Humans; Indoles; Medical Oncology; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Retrospective Studies; Sirolimus; Sunitinib	2010
Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas. Cancer treatment reviews, 2010, Volume: 36 Suppl 3 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Neuroendocrine; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Pancreatic Neoplasms; Pyrroles; Receptors, Somatostatin; Sirolimus; Somatostatin; Sunitinib; Vascular Endothelial Growth Factor A	2010
New therapeutic options for metastatic malignant insulinomas. Clinical endocrinology, 2011, Volume: 75, Issue:3 Topics: Antineoplastic Agents; Everolimus; Humans; Indoles; Insulinoma; Liver Neoplasms; Pancreatic Neoplasms; Pyrroles; Radiopharmaceuticals; Receptors, Somatostatin; Sirolimus; Somatostatin; Sunitinib	2011
Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours. Endocrine, 2011, Volume: 40, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Endocrine Gland Neoplasms; Everolimus; Gastrointestinal Neoplasms; Humans; Indoles; Molecular Targeted Therapy; Neovascularization, Pathologic; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases	2011
Sunitinib for advanced pancreatic neuroendocrine tumors. Expert review of anticancer therapy, 2011, Volume: 11, Issue:12 Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib	2011
Advances in the treatment of pancreatic neuroendocrine tumours. QJM : monthly journal of the Association of Physicians, 2012, Volume: 105, Issue:9 Topics: Antineoplastic Agents; Disease-Free Survival; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib	2012
Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different? Current oncology reports, 2012, Volume: 14, Issue:3 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoid Tumor; Combined Modality Therapy; Dacarbazine; Embolization, Therapeutic; Everolimus; Humans; Immunosuppressive Agents; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Streptozocin; Sunitinib; Temozolomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factors; Yttrium Radioisotopes	2012
Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook. Molecular diagnosis & therapy, 2012, Jun-01, Volume: 16, Issue:3 Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Everolimus; Gastrointestinal Neoplasms; Humans; Indoles; Interleukin-8; Molecular Targeted Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2012
New targeted agents in gastroenteropancreatic neuroendocrine tumors. Targeted oncology, 2012, Volume: 7, Issue:2 Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Everolimus; Gastrointestinal Neoplasms; Humans; Indoles; Molecular Targeted Therapy; Neovascularization, Pathologic; Pancreatic Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases	2012
A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors. Cancer discovery, 2011, Volume: 1, Issue:3 Topics: Clinical Trials as Topic; Drug Discovery; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib	2011
Sunitinib in pancreatic neuroendocrine tumors. Targeted oncology, 2012, Volume: 7, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib	2012
Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors. Oncology, 2012, Volume: 83, Issue:3 Topics: Antineoplastic Agents; Benzenesulfonates; Cell Differentiation; ErbB Receptors; Everolimus; Histone Deacetylases; Humans; Immunologic Factors; Indazoles; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptors, Somatostatin; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2012
Sunitinib and pancreatic neuroendocrine tumours. More assessment needed. Prescrire international, 2012, Volume: 21, Issue:127 Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Indoles; Pancreatic Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Sunitinib	2012
Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies. Targeted oncology, 2012, Volume: 7, Issue:3 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Resistance, Neoplasm; Etoposide; Everolimus; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Medical Oncology; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2012
[Current status and therapeutic strategy for pancreatic neuroendocrine tumors in Japan]. Fukuoka igaku zasshi = Hukuoka acta medica, 2012, Volume: 103, Issue:7 Topics: Antineoplastic Agents; Dacarbazine; Digestive System Surgical Procedures; Everolimus; Humans; Immunosuppressive Agents; Indoles; Japan; Molecular Targeted Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Somatostatin; Streptozocin; Sunitinib; Temozolomide	2012
Pancreatic neuroendocrine neoplasms. Minerva gastroenterologica e dietologica, 2012, Volume: 58, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chromogranin A; Endosonography; Everolimus; Germany; Hepatectomy; Humans; Incidence; Indoles; Liver Transplantation; Magnetic Resonance Imaging; Multimodal Imaging; Neoplasm Grading; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron-Emission Tomography; Prevalence; Prognosis; Pyrroles; Sirolimus; Somatostatin; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome	2012
Pancreatic neuroendocrine tumors: signal pathways and targeted therapies. Current molecular medicine, 2013, Volume: 13, Issue:3 Topics: Antineoplastic Agents; Everolimus; Humans; Immunosuppressive Agents; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Signal Transduction; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases	2013
Systemic therapy for advanced pancreatic neuroendocrine tumors. Seminars in oncology, 2013, Volume: 40, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Somatostatin; Sunitinib; Treatment Outcome	2013

Trials

13 trial(s) available for pyrroles and Cancer of Pancreas

Article	Year
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. Science & sports, 2023, Apr-04 Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide	2023
Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:17 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Female; Humans; Indoles; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Pyrroles; Sunitinib; Survival Analysis	2013
Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical tria BMJ open, 2015, May-19, Volume: 5, Issue:5 Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Cytoreduction Surgical Procedures; Digestive System Neoplasms; Disease-Free Survival; Everolimus; Gastrointestinal Neoplasms; Gastrointestinal Tract; Genotype; Humans; Indoles; Mutation; Neuroendocrine Tumors; Pancreas; Pancreatic Neoplasms; Prospective Studies; Pyrroles; Research Design; Sunitinib	2015
Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Feb-01, Volume: 28, Issue:2 Topics: Antineoplastic Agents; Cross-Sectional Studies; Disease-Free Survival; Double-Blind Method; Humans; Indoles; Kaplan-Meier Estimate; Neuroendocrine Tumors; Pancreatic Neoplasms; Proportional Hazards Models; Pyrroles; Sunitinib; Survival Rate	2017
Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial. Targeted oncology, 2016, Volume: 11, Issue:6 Topics: Antineoplastic Agents; Female; Humans; Indoles; Male; Neuroendocrine Tumors; Pancreatic Neoplasms; Patient Reported Outcome Measures; Pyrroles; Quality of Life; Retrospective Studies; Sunitinib	2016
Activity of sunitinib in patients with advanced neuroendocrine tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jul-10, Volume: 26, Issue:20 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoid Tumor; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunohistochemistry; Indoles; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Quality of Life; Risk Assessment; Single-Blind Method; Sunitinib; Survival Analysis; Treatment Outcome	2008
A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). The oncologist, 2010, Volume: 15, Issue:12 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Pyrroles; Salvage Therapy; Sunitinib; Survival Rate; Treatment Outcome	2010
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. The New England journal of medicine, 2011, Feb-10, Volume: 364, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Double-Blind Method; Female; Humans; Indoles; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Quality of Life; Receptors, Vascular Endothelial Growth Factor; Sunitinib	2011
Sunitinib: in advanced, well differentiated pancreatic neuroendocrine tumors. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2011, Oct-01, Volume: 25, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Indoles; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib	2011
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Investigational new drugs, 2012, Volume: 30, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Combinations; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lactones; Lung Neoplasms; Male; Melanoma; Middle Aged; Pancreatic Neoplasms; Proteasome Inhibitors; Pyrroles; Vorinostat	2012
Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:12 Topics: Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Hemangioblastoma; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Pilot Projects; Pyrroles; Radiography; Sunitinib; Treatment Outcome; von Hippel-Lindau Disease; Young Adult	2011
FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors. The oncologist, 2012, Volume: 17, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Drug Approval; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib; United States; United States Food and Drug Administration	2012
Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Investigational new drugs, 2013, Volume: 31, Issue:5 Topics: Adult; Aged; Angiogenesis Inhibitors; Asian People; Biomarkers, Tumor; Chromogranin A; Female; Gastrins; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib; Treatment Outcome	2013

Other Studies

142 other study(ies) available for pyrroles and Cancer of Pancreas

Article	Year
10Z‑Hymenialdisine inhibits angiogenesis by suppressing NF‑κB activation in pancreatic cancer cell lines. Oncology reports, 2022, Volume: 47, Issue:3 Topics: Angiogenesis Inhibitors; Animals; Azepines; Cell Line, Tumor; Disease Models, Animal; Humans; Mice; Neovascularization, Pathologic; NF-kappa B; Pancreatic Neoplasms; Pyrroles	2022
Combined surgical and medical management of a cat with gastrinoma. The Journal of small animal practice, 2022, Volume: 63, Issue:8 Topics: Animals; Cat Diseases; Cats; Duodenal Neoplasms; Female; Gastrinoma; Gastrins; Omeprazole; Pancreatic Neoplasms; Pyrroles	2022
Enhanced photothermal and chemotherapy of pancreatic tumors by degrading the extracellular matrix. Colloids and surfaces. B, Biointerfaces, 2023, Volume: 221 Topics: Doxorubicin; Extracellular Matrix; Humans; Pancreatic Neoplasms; Polymers; Pyrroles	2023
Discovery of a pyrrole-pyridinimidazole derivative as novel SIRT6 inhibitor for sensitizing pancreatic cancer to gemcitabine. Cell death & disease, 2023, 08-04, Volume: 14, Issue:8 Topics: Apoptosis; Cell Line, Tumor; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Pyrroles; Sirtuins; Xenograft Model Antitumor Assays	2023
Anticancer Activities of DNA-Alkylating Pyrrole-Imidazole Polyamide Analogs Targeting RUNX Transcription Factors against Journal of medicinal chemistry, 2023, 09-14, Volume: 66, Issue:17 Topics: Animals; DNA; Humans; Imidazoles; Mice; Nylons; Pancreatic Neoplasms; Pyrroles; Transcription Factors; Tumor Suppressor Protein p53	2023
Cellular Pharmacodynamics of a Novel Pyrrolo[3,2- Molecular pharmacology, 2020, Volume: 97, Issue:1 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Membrane; Cytosol; Drug Screening Assays, Antitumor; Gene Knockout Techniques; Glutathione; Glycine Hydroxymethyltransferase; Humans; Leucovorin; Mitochondria; Pancreatic Neoplasms; Purine Nucleotides; Pyrimidines; Pyrroles; Reactive Oxygen Species; Serine; Tetrahydrofolates	2020
Development of a Tumor-Responsive Nanopolyplex Targeting Pancreatic Cancer Cells and Stroma. ACS applied materials & interfaces, 2019, Dec-11, Volume: 11, Issue:49 Topics: Animals; Caprylates; Cell Line, Tumor; Cell Proliferation; Humans; Hydrophobic and Hydrophilic Interactions; Mice; Nanoparticles; Pancreatic Neoplasms; Pancreatic Stellate Cells; Pyrazoles; Pyrroles; Stromal Cells; Sulfides; Tumor Microenvironment; Xenograft Model Antitumor Assays	2019
Integrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus. Theranostics, 2020, Volume: 10, Issue:7 Topics: Animals; Antigens, Neoplasm; Apoptosis; Benzodiazepines; Capsid Proteins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; DNA Damage; Female; Humans; Integrins; Mice; Mice, Knockout; Pancreatic Neoplasms; Peptides; Pyrroles	2020
Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase inhibitor in pancreatic cancer cells. Bioorganic & medicinal chemistry letters, 2021, 02-01, Volume: 33 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 4; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Structure-Activity Relationship	2021
Evaluation of palliative therapy, alone or in combination with toceranib phosphate, in dogs diagnosed with metastatic or recurrent beta-cell neoplasia. New Zealand veterinary journal, 2021, Volume: 69, Issue:4 Topics: Animals; Antineoplastic Agents; Dog Diseases; Dogs; Hospitals, Animal; Hospitals, Teaching; Indoles; Insulinoma; Palliative Care; Pancreatic Neoplasms; Pyrroles; Retrospective Studies	2021
Toceranib phosphate (Palladia) for the treatment of canine exocrine pancreatic adenocarcinoma. BMC veterinary research, 2021, Aug-11, Volume: 17, Issue:1 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Dog Diseases; Dogs; Female; Indoles; Male; Pancreatic Neoplasms; Pyrroles; Retrospective Studies	2021
Synthetic 8-hydroxydeoxyguanosine inhibited metastasis of pancreatic cancer through concerted inhibitions of ERM and Rho-GTPase. Free radical biology & medicine, 2017, Volume: 110 Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 8-Hydroxy-2'-Deoxyguanosine; Acetylcysteine; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Claudin-1; Deoxyguanosine; DNA-Binding Proteins; Epithelial-Mesenchymal Transition; Focal Adhesion Kinase 1; Gene Expression Regulation, Neoplastic; GTPase-Activating Proteins; Humans; Hyaluronan Receptors; Imidazoles; Lung Neoplasms; Matrix Metalloproteinases; Mice; Mice, Nude; NADPH Oxidases; Pancreatic Neoplasms; Pyrroles; rho-Associated Kinases; Signal Transduction; Transcription Factors; Vimentin; Xenograft Model Antitumor Assays; Zonula Occludens-1 Protein	2017
Treatment Patterns and Burden of Illness in Patients Initiating Targeted Therapy or Chemotherapy for Pancreatic Neuroendocrine Tumors. Pancreas, 2017, Volume: 46, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Cost of Illness; Everolimus; Humans; Indoles; Middle Aged; Molecular Targeted Therapy; Nausea; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Retrospective Studies; Sunitinib; Thrombocytopenia; Vomiting; Young Adult	2017
Autophagy Inhibition Improves Sunitinib Efficacy in Pancreatic Neuroendocrine Tumors via a Lysosome-dependent Mechanism. Molecular cancer therapeutics, 2017, Volume: 16, Issue:11 Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Autophagy; Cell Line, Tumor; Cell Membrane Permeability; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Gene Knockdown Techniques; Humans; Indoles; Lysosomal-Associated Membrane Protein 2; Lysosomes; Mice; Neovascularization, Pathologic; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib	2017
Inhibition of p21 activated kinase enhances tumour immune response and sensitizes pancreatic cancer to gemcitabine. International journal of oncology, 2018, Volume: 52, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyrroles; Random Allocation	2018
Solid pseudopapillary tumour (Frantz's tumour) of the pancreas in childhood: successful management of late liver metastases with sunitinib and chemoembolisation. BMJ case reports, 2017, Dec-22, Volume: 2017 Topics: Adolescent; Antineoplastic Agents; Carcinoma, Papillary; Combined Modality Therapy; Embolization, Therapeutic; Female; Humans; Indoles; Liver Neoplasms; Magnetic Resonance Imaging; Pancreas; Pancreatic Neoplasms; Pancreaticoduodenectomy; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome	2017
Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2018, Volume: 18, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Humans; Indoles; Italy; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome	2018
Safety signal detection and evaluation in clinical development programs: A case study of tofacitinib. Pharmacology research & perspectives, 2018, Volume: 6, Issue:1 Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Clinical Trials as Topic; Feasibility Studies; Female; Humans; Incidence; Janus Kinase Inhibitors; Japan; Male; Middle Aged; Pancreatic Neoplasms; Pharmacovigilance; Piperidines; Product Surveillance, Postmarketing; Pyrimidines; Pyrroles	2018
An Advanced Well-differentiated Pancreatic Neuroendocrine Carcinoma (NET-G3) Associated with Von Hippel-Lindau Disease. Internal medicine (Tokyo, Japan), 2018, Jul-15, Volume: 57, Issue:14 Topics: Antineoplastic Agents; Asian People; Carcinoma, Neuroendocrine; Everolimus; Female; Humans; Indoles; Liver Neoplasms; Middle Aged; Pancreatic Neoplasms; Pyrroles; Sunitinib; Treatment Outcome; von Hippel-Lindau Disease	2018
When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report. Journal of medical case reports, 2018, Mar-20, Volume: 12, Issue:1 Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Neoplasms, Second Primary; Pancreas; Pancreatic Neoplasms; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome	2018
Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms. Journal of cancer research and clinical oncology, 2018, Volume: 144, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Grading; Neuroendocrine Tumors; Pancreatic Neoplasms; Proportional Hazards Models; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Young Adult	2018
Effects of obatoclax combined with gemcitabine on the biological activity of pancreatic cancer cells under hypoxic conditions. Molecular medicine reports, 2018, Volume: 18, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Cadherins; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Deoxycytidine; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Indoles; Neoplasm Invasiveness; Pancreatic Neoplasms; Pyrroles; Tumor Suppressor Protein p53	2018
Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasis. Science translational medicine, 2018, 05-16, Volume: 10, Issue:441 Topics: Animals; Cell Line, Tumor; Cell Nucleolus; Cell Proliferation; Chromatin; DNA, Ribosomal; Humans; Male; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Peptide Elongation Factor 1; Promoter Regions, Genetic; Pyrimidines; Pyrroles; RNA Polymerase I; RNA Precursors; Survival Analysis; Transcription, Genetic; Xenograft Model Antitumor Assays	2018
DCE-MRI of Sunitinib-Induced Changes in Tumor Microvasculature and Hypoxia: A Study of Pancreatic Ductal Adenocarcinoma Xenografts. Neoplasia (New York, N.Y.), 2018, Volume: 20, Issue:7 Topics: Animals; Biomarkers; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Contrast Media; Disease Models, Animal; Female; Humans; Hypoxia; Image Enhancement; Immunohistochemistry; Indoles; Magnetic Resonance Imaging; Male; Mice; Neovascularization, Pathologic; Pancreatic Neoplasms; Pyrroles; Sunitinib; Tumor Microenvironment; Xenograft Model Antitumor Assays	2018
Long-term clinical control of feline pancreatic carcinoma with toceranib phosphate. The Canadian veterinary journal = La revue veterinaire canadienne, 2018, Volume: 59, Issue:7 Topics: Animals; Antineoplastic Agents; Carcinoma; Cat Diseases; Cats; Female; Indoles; Pancreatic Neoplasms; Pyrroles	2018
TGF-β signaling promotes tube-structure-forming growth in pancreatic duct adenocarcinoma. Scientific reports, 2019, 08-02, Volume: 9, Issue:1 Topics: Animals; Benzamides; Carcinogenesis; Carcinoma, Pancreatic Ductal; Cell Culture Techniques; Cell Line, Tumor; Dioxoles; Disease Models, Animal; Humans; Mice; Mice, Transgenic; Pancreatic Neoplasms; Pyrazoles; Pyrroles; Recombinant Proteins; RNA-Seq; Signal Transduction; Spheroids, Cellular; Transforming Growth Factor beta1	2019
Sunitinib for the treatment of metastatic paraganglioma and vasoactive intestinal polypeptide-producing tumor (VIPoma). Pancreas, 2013, Volume: 42, Issue:2 Topics: Abdominal Neoplasms; Aged; Antineoplastic Agents; Biomarkers, Tumor; Child; Drug Administration Schedule; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Pancreatic Neoplasms; Paraganglioma; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Time Factors; Treatment Outcome; Vipoma	2013
Improvement of actinic keratosis associated with sunitinib therapy for metastatic renal cell carcinoma. International journal of dermatology, 2013, Volume: 52, Issue:11 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Keratosis, Actinic; Kidney Neoplasms; Lung Neoplasms; Male; Pancreatic Neoplasms; Pyrroles; Sunitinib	2013
Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice. Cancer research, 2013, Jun-15, Volume: 73, Issue:12 Topics: Animals; Antibodies; Antineoplastic Agents; Gene Expression Regulation, Neoplastic; Immunohistochemistry; Indoles; Lymphatic Metastasis; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microscopy, Confocal; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-met; Pyrazines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sunitinib; Triazoles; Vascular Endothelial Growth Factor C	2013
Sunitinib-induced hyperammonaemia in a patient with pancreatic neuroendocrine tumour. Journal of clinical pharmacy and therapeutics, 2013, Volume: 38, Issue:4 Topics: Humans; Hyperammonemia; Indoles; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib	2013
Sunitinib malate as first-line treatment for an advanced, poorly differentiated pancreatic neuroendocrine tumor. Future oncology (London, England), 2013, Volume: 9, Issue:6 Topics: Disease-Free Survival; Female; Humans; Indoles; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis; Pyrroles; Sunitinib	2013
Validated RP-HPLC method for the simultaneous analysis of gemcitabine and LY-364947 in liposomal formulations. Current drug targets, 2013, Volume: 14, Issue:9 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cattle; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Deoxycytidine; Drug Stability; Gemcitabine; Liposomes; Pancreatic Neoplasms; Pyrazoles; Pyrroles	2013
Neuroendocrine tumors: treatment updates. JOP : Journal of the pancreas, 2013, Jul-10, Volume: 14, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Everolimus; Humans; Indoles; Intestinal Neoplasms; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Pyrroles; Sirolimus; Stomach Neoplasms; Sunitinib; Treatment Outcome	2013
Novel agents and future prospects in the treatment of pancreatic adenocarcinoma. JOP : Journal of the pancreas, 2013, Jul-10, Volume: 14, Issue:4 Topics: Adenocarcinoma; Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Indoles; Niacinamide; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sunitinib; Treatment Outcome	2013
Proteomic strategy for probing complementary lethality of kinase inhibitors against pancreatic cancer. Proteomics, 2013, Volume: 13, Issue:23-24 Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Survival; Dasatinib; Drug Screening Assays, Antitumor; Drug Synergism; Heme Oxygenase-1; Humans; Imatinib Mesylate; Indoles; Pancreatic Neoplasms; Piperazines; Protein Kinase Inhibitors; Proteome; Pyrimidines; Pyrroles; Spectrometry, Mass, Electrospray Ionization; Sunitinib; Tandem Mass Spectrometry; Thiazoles	2013
BSA nanoparticle loaded atorvastatin calcium--a new facet for an old drug. PloS one, 2014, Volume: 9, Issue:2 Topics: Adult; Animals; Anticholesteremic Agents; Antineoplastic Agents; Atorvastatin; Cattle; Cell Line, Tumor; Cell Survival; Hemolysis; Heptanoic Acids; Humans; Kinetics; Microscopy, Confocal; Microscopy, Electron, Scanning; Molecular Docking Simulation; Nanoparticles; Pancreatic Neoplasms; Pyrroles; Reactive Oxygen Species; Serum Albumin, Bovine; Spectrometry, Fluorescence; Spectroscopy, Fourier Transform Infrared; Time Factors	2014
Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer. Cancer letters, 2014, Jun-28, Volume: 348, Issue:1-2 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; BRCA1 Protein; BRCA2 Protein; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Female; Humans; Indoles; Mice, Inbred BALB C; Mice, Nude; Necrosis; Pancreatic Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Time Factors; Xenograft Model Antitumor Assays	2014
Methods for adjusting for bias due to crossover in oncology trials. PharmacoEconomics, 2014, Volume: 32, Issue:6 Topics: Antineoplastic Agents; Bias; Cost-Benefit Analysis; Cross-Over Studies; Humans; Indoles; Kaplan-Meier Estimate; Models, Statistical; Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib	2014
A triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors. International journal of oncology, 2014, Volume: 44, Issue:6 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Celecoxib; Cell Line, Tumor; Cell Proliferation; Female; Heptanoic Acids; Humans; Injections, Intraperitoneal; Mice; Mice, SCID; Neoplasms, Experimental; Pancreatic Neoplasms; Pyrazoles; Pyrroles; Quinolones; Sulfonamides; Xenograft Model Antitumor Assays	2014
Tyrosine kinase inhibitor sunitinib allows insulin independence in long-standing type 1 diabetes. Diabetes care, 2014, Volume: 37, Issue:5 Topics: Antineoplastic Agents; Diabetes Mellitus, Type 1; Fatal Outcome; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Indoles; Insulin Aspart; Insulin Glargine; Insulin, Long-Acting; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib	2014
The inhibition of SRC family kinase suppresses pancreatic cancer cell proliferation, migration, and invasion. Pancreas, 2014, Volume: 43, Issue:5 Topics: Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; Neoplasm Invasiveness; Neoplasm Proteins; Pancreatic Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-fyn; Proto-Oncogene Proteins c-hck; Proto-Oncogene Proteins c-yes; Proto-Oncogene Proteins pp60(c-src); Pyrimidines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; src-Family Kinases	2014
Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Aug-01, Volume: 20, Issue:15 Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Movement; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Thiazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2014
Use of sunitinib in a 30-year-old woman with pancreatic neuroendocrine tumors associated with Von Hippel-Lindau syndrome. Journal of clinical gastroenterology, 2015, Volume: 49, Issue:1 Topics: Adult; Antineoplastic Agents; Female; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib; von Hippel-Lindau Disease	2015
MicroRNA modulation combined with sunitinib as a novel therapeutic strategy for pancreatic cancer. International journal of nanomedicine, 2014, Volume: 9 Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Drug Synergism; Gene Expression Regulation, Neoplastic; Genetic Therapy; Humans; Indoles; MicroRNAs; Oligonucleotides, Antisense; Pancreatic Neoplasms; Phosphatidylcholines; Pyrroles; Sunitinib; Transfection	2014
Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors. Cancer treatment reviews, 2014, Volume: 40, Issue:10 Topics: Antineoplastic Agents; Cardiovascular Diseases; Drug Administration Schedule; Fatigue; Hand-Foot Syndrome; Humans; Indoles; Neuroendocrine Tumors; Neutropenia; Pancreatic Neoplasms; Pyrroles; Stomatitis; Sunitinib; Thyroid Diseases	2014
Sunitinib achieved fast and sustained control of VIPoma symptoms. European journal of endocrinology, 2015, Volume: 172, Issue:1 Topics: Adult; Antineoplastic Agents; Fatal Outcome; Female; Humans; Indoles; Male; Middle Aged; Pancreatic Neoplasms; Pyrroles; Sunitinib; Time Factors; Vipoma	2015
Combination of chloroquine and GX15-070 (obatoclax) results in synergistic cytotoxicity against pancreatic cancer cells. Oncology reports, 2014, Volume: 32, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; bcl-X Protein; Cell Line, Tumor; Chloroquine; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Indoles; Myeloid Cell Leukemia Sequence 1 Protein; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrroles	2014
Sunitinib-induced complete response in metastatic renal cancer expressing neuroendocrine markers: a new predictive factor? Anticancer research, 2014, Volume: 34, Issue:12 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Pancreatic Neoplasms; Positron-Emission Tomography; Pyrroles; Sunitinib	2014
Assessment of the safety and efficiency of sunitinib malate in metastatic neuroendocrine tumours of the pancreas (NEN G1/G2) depending on the number and type of earlier therapeutic lines - initial report. Endokrynologia Polska, 2014, Volume: 65, Issue:6 Topics: Antineoplastic Agents; Disease Progression; Disease-Free Survival; Humans; Indoles; Leukopenia; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib	2014
[Erlotinib, sunitinib, and everolimus]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73 Suppl 3 Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Erlotinib Hydrochloride; Everolimus; Humans; Indoles; Pancreatic Neoplasms; Pyrroles; Quinazolines; Sirolimus; Sunitinib	2015
Sequencing and combining systemic therapies for pancreatic neuroendocrine tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, May-10, Volume: 33, Issue:14 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Diarrhea; Drug Administration Schedule; Everolimus; Humans; Indoles; Ki-67 Antigen; Liver Neoplasms; Male; Middle Aged; Mitotic Index; Neoplasm Grading; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Somatostatin; Sunitinib; Tomography, X-Ray Computed	2015
Targeting pancreatitis blocks tumor-initiating stem cells and pancreatic cancer progression. Oncotarget, 2015, Jun-20, Volume: 6, Issue:17 Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Arachidonic Acid; Carcinoma in Situ; Carcinoma, Pancreatic Ductal; Cell Proliferation; Ceruletide; Cyclooxygenase 2; Disease Models, Animal; Disease Progression; Doublecortin-Like Kinases; Lipoxygenase Inhibitors; Mice; Mice, Knockout; MicroRNAs; Neoplastic Stem Cells; Pancreatic Neoplasms; Pancreatitis; Protein Serine-Threonine Kinases; Pyrroles	2015
Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU international, 2016, Volume: 117, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome	2016
Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma. Oncotarget, 2015, Oct-20, Volume: 6, Issue:32 Topics: Animals; Antineoplastic Agents; Arachidonate 5-Lipoxygenase; Carcinoma, Pancreatic Ductal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Synergism; ErbB Receptors; Female; Gefitinib; Lipoxygenase Inhibitors; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pancreatic Neoplasms; Pyrroles; Quinazolines; Signal Transduction	2015
New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors. Clinical advances in hematology & oncology : H&O, 2015, Volume: 13, Issue:5 Suppl 5 Topics: Antineoplastic Agents; Everolimus; Hormones; Humans; Indoles; Intestinal Neoplasms; Intestines; Molecular Targeted Therapy; Neuroendocrine Tumors; Octreotide; Pancreas; Pancreatic Neoplasms; Pyrroles; Somatostatin; Stomach; Stomach Neoplasms; Sunitinib	2015
Inhibition of Eph receptor A4 by 2,5-dimethylpyrrolyl benzoic acid suppresses human pancreatic cancer growing orthotopically in nude mice. Oncotarget, 2015, Dec-01, Volume: 6, Issue:38 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Benzoates; Benzoic Acid; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrroles; Receptor, EphA4; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Xenograft Model Antitumor Assays	2015
Drug therapy: Preclinical oncology - reporting transparency needed. Nature reviews. Clinical oncology, 2016, Volume: 13, Issue:1 Topics: Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Carcinoma, Renal Cell; Clinical Trials as Topic; Evidence-Based Medicine; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Medical Oncology; Meta-Analysis as Topic; Neoplasms; Pancreatic Neoplasms; Practice Guidelines as Topic; Pyrroles; Research Design; Research Report; Stomach Neoplasms; Sunitinib; Treatment Outcome	2016
Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpoint. Oncotarget, 2016, Apr-05, Volume: 7, Issue:14 Topics: Adenocarcinoma; Cell Cycle Proteins; Cell Line, Tumor; Cohort Studies; DNA Replication; G1 Phase Cell Cycle Checkpoints; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Piperidones; Protein Serine-Threonine Kinases; Pyrroles; Transfection	2016
Attainment of a Long-term Favorable Outcome by Sunitinib Treatment for Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Associated with von Hippel-Lindau Disease. Internal medicine (Tokyo, Japan), 2016, Volume: 55, Issue:6 Topics: Adenoma, Islet Cell; Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Fatal Outcome; Genes, Tumor Suppressor; Germ-Line Mutation; Humans; Indoles; Kidney Neoplasms; Male; Pancreatic Neoplasms; Pyrroles; Signal Transduction; Sunitinib; Time Factors; Vascular Endothelial Growth Factor A; von Hippel-Lindau Disease	2016
Sunitinib Efficacy in Patients with Advanced pNET in Clinical Practice. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2016, Volume: 48, Issue:9 Topics: Adult; Aged; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Indoles; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Practice Patterns, Physicians'; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome	2016
Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling. Cell reports, 2016, 05-10, Volume: 15, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glucose; Glutamine; Glycolysis; Humans; Imidazoles; Indazoles; Indoles; Intestinal Neoplasms; Lactic Acid; Membrane Transport Proteins; Mice; Models, Biological; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Signal Transduction; Sirolimus; Stomach Neoplasms; Sunitinib; TOR Serine-Threonine Kinases; Up-Regulation	2016
The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer. Oncotarget, 2016, 07-26, Volume: 7, Issue:30 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Indoles; Mice; Neovascularization, Pathologic; Pancreatic Neoplasms; Pyrroles; Sunitinib	2016
Efficiency of Sunitinib in Chinese Patients with Advanced Progressive Pancreatic Neuroendocrine Tumor. Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 2016, 06-10, Volume: 38, Issue:3 Topics: Antineoplastic Agents; Disease-Free Survival; Humans; Indoles; Pancreatic Neoplasms; Pyrroles; Sunitinib	2016
In vitro investigation of multidrug nanoparticles for combined therapy with gemcitabine and a tyrosine kinase inhibitor: Together is not better. Biochimie, 2016, Volume: 130 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Indoles; Microscopy, Electron, Transmission; Nanoparticles; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib	2016
Metachronous pancreatic metastases from renal cell carcinoma: is there a place of Active-Surveillance before deferred deliberately Molecular Target Agent? World journal of surgical oncology, 2016, Aug-23, Volume: 14, Issue:1 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Neoplasms, Second Primary; Pancreatic Neoplasms; Prognosis; Pyrroles; Sunitinib	2016
Targeted Therapies Provide Treatment Options for Poorly Differentiated Pancreatic Neuroendocrine Carcinomas. Oncology, 2017, Volume: 92, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Neuroendocrine; Cell Differentiation; Everolimus; Female; Humans; Indoles; Male; Middle Aged; Molecular Targeted Therapy; Pancreatic Neoplasms; Pyrroles; Sunitinib; TOR Serine-Threonine Kinases	2017
Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor. Cancer chemotherapy and pharmacology, 2017, Volume: 79, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Intestinal Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Retrospective Studies; Stomach Neoplasms; Sunitinib	2017
Treatment of metastatic pancreatic neuroendocrine tumors: relevance of ENETS 2016 guidelines. Endocrine-related cancer, 2017, Volume: 24, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Everolimus; Female; Guidelines as Topic; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis; Pyrroles; Retrospective Studies; Societies, Medical; Sunitinib; Young Adult	2017
Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-Differentiated Neuroendocrine Tumours Resistant to Prior Treatments. Neuroendocrinology, 2017, Volume: 105, Issue:4 Topics: Antineoplastic Agents; Everolimus; Female; Humans; Indoles; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Retrospective Studies; Severity of Illness Index; Sunitinib; Treatment Outcome	2017
Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria? BMC cancer, 2017, 02-23, Volume: 17, Issue:1 Topics: Adult; Antineoplastic Agents; Female; Humans; Indoles; Intestinal Neoplasms; Kaplan-Meier Estimate; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Retrospective Studies; Stomach Neoplasms; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome	2017
SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. International journal of radiation oncology, biology, physics, 2008, Jul-01, Volume: 71, Issue:3 Topics: Adenocarcinoma; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Humans; Indoles; Pancreatic Neoplasms; Pyrroles; Radiation Tolerance; Radiation-Sensitizing Agents; Sunitinib	2008
Severe gastrointestinal hemorrhage due to metastatic renal cell carcinoma to the pancreas successfully controlled by transarterial embolization and adjuvant administration of Sunitinib Malate. Hinyokika kiyo. Acta urologica Japonica, 2008, Volume: 54, Issue:4 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Embolization, Therapeutic; Gastrointestinal Hemorrhage; Humans; Indoles; Kidney Neoplasms; Male; Pancreatic Neoplasms; Pyrroles; Sunitinib	2008
Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Aug-15, Volume: 14, Issue:16 Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cetuximab; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lactones; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrroles; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays	2008
BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Jan-01, Volume: 15, Issue:1 Topics: Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; BH3 Interacting Domain Death Agonist Protein; Caspases; Cell Line, Tumor; Cytochromes c; Humans; Indoles; Myeloid Cell Leukemia Sequence 1 Protein; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrroles; TNF-Related Apoptosis-Inducing Ligand	2009
Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series. European urology, 2009, Volume: 56, Issue:1 Topics: Anorexia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Bevacizumab; Bone Neoplasms; Carcinoma, Renal Cell; Diarrhea; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mucositis; Pancreatic Neoplasms; Pyrroles; Salvage Therapy; Sunitinib	2009
Selective cytotoxic activity of the marine-derived batzelline compounds against pancreatic cancer cell lines. Anti-cancer drugs, 2009, Volume: 20, Issue:2 Topics: Alkaloids; Animals; Cell Cycle; Cell Line, Tumor; Cell Survival; Cytotoxins; DNA; DNA Topoisomerases, Type II; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Intercalating Agents; Pancreatic Neoplasms; Porifera; Pyrroles; Pyrroloiminoquinones; Quinolines; Substrate Specificity; Topoisomerase II Inhibitors	2009
Response of renal cell carcinoma pancreatic metastasis to sunitinib treatment: a retrospective analysis. The Journal of urology, 2009, Volume: 181, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Pyrroles; Retrospective Studies; Sunitinib	2009
Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: an experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy. Oncology reports, 2009, Volume: 22, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Line, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Epidermal Growth Factor; fas Receptor; Gemcitabine; Indoles; Male; Mice; Microvessels; Neovascularization, Pathologic; Pancreatic Neoplasms; Placenta Growth Factor; Pregnancy Proteins; Protein Kinase Inhibitors; Pyrroles; Radiotherapy, Adjuvant; Sunitinib; Time Factors; Vascular Endothelial Growth Factor A	2009
Statins inhibit Akt/PKB signaling via P2X7 receptor in pancreatic cancer cells. Biochemical pharmacology, 2009, Nov-01, Volume: 78, Issue:9 Topics: Apoptosis; Atorvastatin; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Fluorouracil; Gemcitabine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrroles; Receptors, Purinergic P2; Receptors, Purinergic P2X7; RNA, Small Interfering; Signal Transduction	2009
Metastatic pancreatic adenocarcinoma and renal cell carcinoma treated with gemcitabine and sunitinib malate. A case report. JOP : Journal of the pancreas, 2009, Sep-04, Volume: 10, Issue:5 Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Neoplasms, Multiple Primary; Pancreatic Neoplasms; Pyrroles; Sunitinib; Treatment Outcome	2009
MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes & development, 2009, Sep-15, Volume: 23, Issue:18 Topics: Angiogenesis Inhibitors; Animals; Cell Differentiation; Cell Proliferation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Indoles; Mice; Mice, Inbred C57BL; MicroRNAs; Neovascularization, Pathologic; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib; Tumor Cells, Cultured	2009
Sunitinib paves the way for targeted therapies in neuroendocrine tumors. Targeted oncology, 2009, Volume: 4, Issue:4 Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoid Tumor; Cell Line, Tumor; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Melphalan; Neovascularization, Pathologic; Neuroendocrine Tumors; Pancreatic Neoplasms; Procarbazine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrroles; Sunitinib; Vinblastine; Xenograft Model Antitumor Assays	2009
Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study. Medical oncology (Northwood, London, England), 2011, Volume: 28, Issue:4 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Everolimus; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib	2011
Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer. Molecular cancer therapeutics, 2010, Volume: 9, Issue:7 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Humans; Indoles; Inhibitory Concentration 50; Kaplan-Meier Estimate; Luminescent Proteins; Mice; Mice, Nude; Neoplasm Metastasis; Pancreatic Neoplasms; Pyrroles; Red Fluorescent Protein; Sunitinib; Tumor Burden; Xenograft Model Antitumor Assays	2010
Changes in resting energy expenditure (REE) as a function of tumor response to sunitinib in a cachexic patient with a metastatic endocrine tumor of the pancreas. Acta oncologica (Stockholm, Sweden), 2010, Volume: 49, Issue:8 Topics: Antineoplastic Agents; Cachexia; Calorimetry, Indirect; Eating; Energy Metabolism; Hepatectomy; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Pyrroles; Rest; Splenectomy; Sunitinib; Treatment Outcome; Weight Loss	2010
Promising advances in the treatment of malignant pancreatic endocrine tumors. The New England journal of medicine, 2011, Feb-10, Volume: 364, Issue:6 Topics: Antineoplastic Agents; Disease Progression; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Quality of Life; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases	2011
Response by Choi criteria to sunitinib plus octreotide LAR in a functional heavily pretreated advanced pancreatic neuroendocrine tumor. Anti-cancer drugs, 2011, Volume: 22, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Indoles; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Pyrroles; Sunitinib	2011
Pancreatic neuroendocrine tumors: role of novel agents. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. JOP : Journal of the pancreas, 2011, Mar-09, Volume: 12, Issue:2 Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Everolimus; Humans; Immunosuppressive Agents; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib; Treatment Outcome	2011
Translational research in pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. JOP : Journal of the pancreas, 2011, Mar-09, Volume: 12, Issue:2 Topics: Animals; Antibodies, Monoclonal; Cell Line, Tumor; Cell Survival; Curcumin; Cyclooxygenase 2 Inhibitors; Epitopes; Focal Adhesion Protein-Tyrosine Kinases; Humans; Mucins; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Pyrroles; Radiation-Sensitizing Agents; Sulfonamides; Translational Research, Biomedical; Xenograft Model Antitumor Assays	2011
Translational medicine: Cancer lessons from mice to humans. Nature, 2011, Mar-17, Volume: 471, Issue:7338 Topics: Animals; Clinical Trials, Phase III as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Everolimus; Humans; Indoles; Mice; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Signal Transduction; Sirolimus; Sunitinib; Survival Rate; Translational Research, Biomedical	2011
Targeted therapies: Good news for advanced-stage pancreatic neuroendocrine tumors. Nature reviews. Clinical oncology, 2011, Volume: 8, Issue:5 Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib	2011
Recent studies show promise for treating rare pancreatic tumors. Journal of the National Cancer Institute, 2011, Apr-20, Volume: 103, Issue:8 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Data Interpretation, Statistical; Disease-Free Survival; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Off-Label Use; Pancreatic Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Rare Diseases; Signal Transduction; Sirolimus; Sunitinib; Survival Analysis; TOR Serine-Threonine Kinases; Treatment Outcome; United States	2011
Advances in pancreatic neuroendocrine tumor treatment. The New England journal of medicine, 2011, 05-12, Volume: 364, Issue:19 Topics: Antineoplastic Agents; Blood Glucose; Diabetes Complications; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib	2011
Advances in pancreatic neuroendocrine tumor treatment. The New England journal of medicine, 2011, 05-12, Volume: 364, Issue:19 Topics: Antineoplastic Agents; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib	2011
Advances in pancreatic neuroendocrine tumor treatment. The New England journal of medicine, 2011, 05-12, Volume: 364, Issue:19 Topics: Animals; Antineoplastic Agents; Diabetes Mellitus, Type 1; Glucagonoma; Humans; Indoles; Insulinoma; Mice; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sunitinib	2011
Advances in pancreatic neuroendocrine tumor treatment. The New England journal of medicine, 2011, 05-12, Volume: 364, Issue:19 Topics: Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib	2011
Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer. HPB : the official journal of the International Hepato Pancreato Biliary Association, 2011, Volume: 13, Issue:9 Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Indoles; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays	2011
Impact of sunitinib pharmacokinetic monitoring in a patient with metastatic renal cell carcinoma undergoing hemodialysis. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:9 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Monitoring; Humans; Indoles; Kidney Neoplasms; Male; Mediastinal Neoplasms; Middle Aged; Pancreatic Neoplasms; Pyrroles; Renal Dialysis; Sunitinib	2011
New target therapies for patients with neuroendocrine tumors of the pancreas. Expert review of gastroenterology & hepatology, 2011, Volume: 5, Issue:5 Topics: Antineoplastic Agents; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib; Treatment Outcome; United States; United States Food and Drug Administration	2011
Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors. Future oncology (London, England), 2011, Volume: 7, Issue:9 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Disease Models, Animal; Everolimus; Humans; Indoles; Mice; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases	2011
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nature nanotechnology, 2011, Oct-23, Volume: 6, Issue:12 Topics: Animals; Antineoplastic Agents; Drug Carriers; Humans; Liposomes; Mice; Mice, Inbred BALB C; Micelles; Organoplatinum Compounds; Pancreatic Neoplasms; Particle Size; Permeability; Polyethylene Glycols; Pyrazoles; Pyrroles; Transforming Growth Factor beta	2011
Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2011, Dec-06, Volume: 108, Issue:49 Topics: Angiogenesis Inhibitors; Animals; Antigens, CD34; Blood Flow Velocity; Carcinoma, Pancreatic Ductal; Clinical Trials as Topic; Contrast Media; Drug Evaluation, Preclinical; Humans; Immunohistochemistry; Indoles; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Microbubbles; Neuroendocrine Tumors; Pancreas; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Prognosis; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sunitinib; Treatment Outcome; Tumor Burden; Ultrasonography	2011
VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells. Annals of surgical oncology, 2012, Volume: 19, Issue:8 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Blotting, Western; Cell Movement; Cells, Cultured; Culture Media, Conditioned; Enzyme-Linked Immunosorbent Assay; Human Umbilical Vein Endothelial Cells; Humans; Indoles; MAP Kinase Kinase 1; MAP Kinase Signaling System; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrroles; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Wound Healing	2012
Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL-KrasG12D/+ mice. International journal of cancer, 2012, Oct-15, Volume: 131, Issue:8 Topics: Animals; Apoptosis; Atorvastatin; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Proliferation; Cytokines; Disease Progression; Fluorescent Antibody Technique; Heptanoic Acids; Humans; Immunoenzyme Techniques; Integrases; Interferon-Stimulated Gene Factor 3, gamma Subunit; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Pyrroles; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured	2012
K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas. Cancer letters, 2012, Sep-01, Volume: 322, Issue:1 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Everolimus; Extracellular Signal-Regulated MAP Kinases; Feedback, Physiological; Female; Humans; Insulin-Like Growth Factor I; MAP Kinase Signaling System; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Mutation; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; Pyrimidines; Pyrroles; ras Proteins; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays	2012
EGCG enhances the therapeutic potential of gemcitabine and CP690550 by inhibiting STAT3 signaling pathway in human pancreatic cancer. PloS one, 2012, Volume: 7, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Catechin; Cell Line, Tumor; Cell Movement; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Piperidines; Pyrimidines; Pyrroles; Signal Transduction; STAT3 Transcription Factor	2012
Steve Jobs's cancer. Pancreatic neuroendocrine tumors are becoming more common (the bad news) and also more treatable (the good news). Harvard health letter, 2012, Volume: 37, Issue:3 Topics: Antineoplastic Agents; Everolimus; Famous Persons; Humans; Indoles; Liver Neoplasms; Neuroendocrine Tumors; Pancreas; Pancreatic Neoplasms; Pyrroles; Risk Factors; Sirolimus; Sunitinib	2012
Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. The Journal of clinical investigation, 2012, Volume: 122, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Cell Hypoxia; Combined Modality Therapy; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Genetic Therapy; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Liver Neoplasms; Lymphatic Metastasis; Mice; Mice, Transgenic; Neoplasm Invasiveness; Neovascularization, Physiologic; Neuroendocrine Tumors; NF-kappa B; Pancreatic Neoplasms; Pericytes; Proto-Oncogene Proteins c-met; Pyrroles; Recombinant Proteins; Semaphorin-3A; Sunitinib; Tumor Burden; Uterine Cervical Neoplasms	2012
Atorvastatin inhibits pancreatic carcinogenesis and increases survival in LSL-KrasG12D-LSL-Trp53R172H-Pdx1-Cre mice. Molecular carcinogenesis, 2013, Volume: 52, Issue:9 Topics: Animals; Atorvastatin; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Epoxide Hydrolases; Heptanoic Acids; Homeodomain Proteins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Ki-67 Antigen; Mice; Pancreas; Pancreatic Neoplasms; Phosphorylation; Prenylation; Proto-Oncogene Proteins c-raf; Proto-Oncogene Proteins p21(ras); Pyrroles; Trans-Activators; Transcriptome; Tumor Suppressor Protein p53	2013
Repression of malignant tumor progression upon pharmacologic IGF1R blockade in a mouse model of insulinoma. Molecular cancer research : MCR, 2012, Volume: 10, Issue:6 Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Immunoblotting; In Situ Nick-End Labeling; Insulinoma; Mice; Mice, Transgenic; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Phosphorylation; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Reverse Transcriptase Polymerase Chain Reaction; Tumor Burden	2012
Chromatin structure determines accessibility of a hairpin polyamide-chlorambucil conjugate at histone H4 genes in pancreatic cancer cells. Bioorganic & medicinal chemistry letters, 2012, Jun-15, Volume: 22, Issue:12 Topics: Acetylation; Antineoplastic Agents, Alkylating; Cell Cycle Checkpoints; Cell Line, Tumor; Chlorambucil; Chromatin; Chromatin Immunoprecipitation; Down-Regulation; HEK293 Cells; Histones; Humans; Imidazoles; Nylons; Organ Specificity; Pancreatic Neoplasms; Pyrroles; RNA, Messenger; Transcription, Genetic	2012
Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models. The Journal of pathology, 2012, Volume: 227, Issue:4 Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antibodies, Anti-Idiotypic; Disease Models, Animal; Drug Therapy, Combination; Genetic Engineering; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Mice; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Vascular Endothelial Growth Factor A	2012
New treatments of pancreatic neuroendocrine tumors: why using them? How to use them? Targeted oncology, 2012, Volume: 7, Issue:2 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib	2012
Rescue of a pathogenic mutant human glucagon receptor by pharmacological chaperones. Journal of molecular endocrinology, 2012, Volume: 49, Issue:2 Topics: Alanine; Asparagine; Cell Membrane; Curcumin; Cyclic AMP; Drug Design; Glucagon; Green Fluorescent Proteins; HEK293 Cells; Humans; Molecular Chaperones; Mutation; Pancreatic Neoplasms; Protein Transport; Pyridines; Pyrroles; Receptors, Glucagon; Serine; Thapsigargin	2012
Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer. PloS one, 2012, Volume: 7, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bevacizumab; Carcinoma, Pancreatic Ductal; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Mice; Mice, Nude; Mice, SCID; Neovascularization, Pathologic; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; Pyrroles; Sunitinib; Tumor Burden; Xenograft Model Antitumor Assays	2012
Implications of the new histological classification (WHO 2010) for pancreatic neuroendocrine neoplasms. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:7 Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib; World Health Organization	2012
[More attention should be paid to the understanding of gastroenteropancreatic neuroendocrine tumors]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:2 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Gastrointestinal Neoplasms; Humans; Indoles; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Peptides, Cyclic; Pyrroles; Sirolimus; Somatostatin; Sunitinib	2012
Preclinical evaluation of anticancer efficacy and pharmacological properties of FBA-TPQ, a novel synthetic makaluvamine analog. Marine drugs, 2012, Volume: 10, Issue:5 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Evaluation, Preclinical; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Protein Binding; Pyrroles; Quinolones; Tissue Distribution; Xenograft Model Antitumor Assays	2012
Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Sep-15, Volume: 18, Issue:18 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Synergism; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Pyrroles; Quinazolines; Sulfonamides	2012
Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States. Journal of medical economics, 2012, Volume: 15 Suppl 1 Topics: Antineoplastic Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Everolimus; Humans; Indoles; Markov Chains; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Quality-Adjusted Life Years; Sirolimus; Sunitinib; Survival Analysis; United States	2012
Targeting neuroendocrine tumor: mixing standard options with novel therapies. Targeted oncology, 2012, Volume: 7, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Humans; Indoles; Medical Oncology; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib; Temozolomide; Treatment Outcome	2012
Oral agents for treatment of patients with advanced pancreatic neuroendocrine tumors: could pharmaeconomic, cost-effectiveness data play a significant role? JOP : Journal of the pancreas, 2013, Jan-10, Volume: 14, Issue:1 Topics: Administration, Oral; Angiogenesis Inhibitors; Antineoplastic Agents; Cost-Benefit Analysis; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Outcome Assessment, Health Care; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib	2013
Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells. BMC cancer, 2013, Jan-31, Volume: 13 Topics: Afatinib; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; Humans; Pancreatic Neoplasms; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-3; Receptor, IGF Type 1	2013
The genetics of neuroendocrine tumors. Seminars in oncology, 2013, Volume: 40, Issue:1 Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Co-Repressor Proteins; DNA Helicases; Everolimus; Humans; Indoles; Molecular Chaperones; Mutation; Neuroendocrine Tumors; Nuclear Proteins; Pancreatic Neoplasms; Proto-Oncogene Mas; Proto-Oncogene Proteins; Pyrroles; Sirolimus; Sunitinib; X-linked Nuclear Protein	2013
Combining antiangiogenic agents with metronomic chemotherapy enhances efficacy against late-stage pancreatic islet carcinomas in mice. Cold Spring Harbor symposia on quantitative biology, 2002, Volume: 67 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Islet Cell; Chronotherapy; Indoles; Matrix Metalloproteinase Inhibitors; Mice; Neovascularization, Pathologic; Pancreatic Neoplasms; Phenylalanine; Protease Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Thiophenes	2002
Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Apr-01, Volume: 10, Issue:7 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Butadienes; Cell Division; Cell Line, Tumor; Chromones; Deoxycytidine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gemcitabine; Humans; Hypoxia; Mitogen-Activated Protein Kinases; Morpholines; Neovascularization, Pathologic; NF-kappa B; Nitriles; Oxygen; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Signal Transduction; Sp1 Transcription Factor; Time Factors; Tyrosine	2004
Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine. European journal of pharmacology, 2004, Sep-13, Volume: 498, Issue:1-3 Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Division; Cell Line; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Endothelial Cells; Female; Gemcitabine; Humans; Immunohistochemistry; Indoles; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Pancreatic Neoplasms; Placenta; Pregnancy; Protein Kinase Inhibitors; Pyrroles; Time Factors; Tissue Culture Techniques; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays	2004
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Feb-10, Volume: 23, Issue:5 Topics: Adenoma, Islet Cell; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Clinical Protocols; Cyclophosphamide; Disease Models, Animal; Endothelial Cells; Imatinib Mesylate; Indoles; Mice; Mice, Transgenic; Neovascularization, Pathologic; Pancreatic Neoplasms; Pericytes; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Remission Induction; Sunitinib	2005
Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jan-15, Volume: 11, Issue:2 Pt 1 Topics: Adult; Aged; Aged, 80 and over; Animals; Apoptosis; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Humans; Indoles; Male; Mice; Mice, Nude; Middle Aged; Neovascularization, Pathologic; Oxindoles; Pancreatic Neoplasms; Phosphorylation; Propionates; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2	2005
IL-1beta-induced pro-apoptotic signalling is facilitated by NCAM/FGF receptor signalling and inhibited by the C3d ligand in the INS-1E rat beta cell line. Diabetologia, 2006, Volume: 49, Issue:8 Topics: Animals; Cell Line; Complement C3d; Hippocampus; Insulin-Secreting Cells; Insulinoma; Interleukin-1; Neural Cell Adhesion Molecules; Neurons; Pancreatic Neoplasms; Phosphorylation; Pyrroles; Rats; Rats, Wistar; Receptor, Fibroblast Growth Factor, Type 1; Receptors, Fibroblast Growth Factor; Recombinant Proteins; Signal Transduction; Tumor Cells, Cultured	2006
LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Molecular cancer therapeutics, 2008, Volume: 7, Issue:4 Topics: Animals; Anoikis; Antimetabolites, Antineoplastic; Apoptosis; Cell Movement; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Receptor, Transforming Growth Factor-beta Type I; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Ribonucleotide Reductases; Signal Transduction; Smad2 Protein; Survival Rate; Transforming Growth Factor beta; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2008
Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis. European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:11 Topics: Angiogenesis Inhibitors; Animals; Cell Communication; Cell Movement; Cell Proliferation; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Pancreatic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Receptor, IGF Type 1	2008
KATP--fact or artefact? New thoughts on the mode of action of the potassium channel openers. Cardiovascular research, 1994, Volume: 28, Issue:6 Topics: Animals; Benzopyrans; Cromakalim; Electrophysiology; Guanidines; Insulinoma; Ion Channel Gating; Muscle, Smooth, Vascular; Pancreatic Neoplasms; Phosphorylation; Picolines; Potassium Channels; Pyrans; Pyrroles; Rats; Tumor Cells, Cultured; Vasodilator Agents	1994
Activation of potassium channels by diazoxide and cromakalim in insulin-secreting cells is dependent upon internal ADP and channel run-down. Biochemical Society transactions, 1993, Volume: 21, Issue:4 Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Benzopyrans; Cell Line; Cromakalim; Diazoxide; Insulin; Insulin Secretion; Insulinoma; Islets of Langerhans; Kinetics; Pancreatic Neoplasms; Potassium Channels; Pyrroles; Tumor Cells, Cultured	1993
Effects of alpha 2-adrenergic agonism, imidazolines, and G-protein on insulin secretion in beta cells. Metabolism: clinical and experimental, 1997, Volume: 46, Issue:10 Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Clonidine; Cricetinae; Glucose; GTP-Binding Proteins; Humans; Imidazoles; Indoles; Insulin; Insulin Secretion; Insulinoma; Islets of Langerhans; Kinetics; Molecular Structure; Oxymetazoline; Pancreatic Neoplasms; Pertussis Toxin; Phentolamine; Pyrroles; Quinolizines; Receptors, Adrenergic, alpha-2; Tumor Cells, Cultured; Virulence Factors, Bordetella	1997
Increase in [Ca2+]i and subsequent insulin release from beta TC3-cells with the L-type Ca(2+)-channel activator, FPL 64176. Advances in experimental medicine and biology, 1997, Volume: 426 Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Animals; Antigens, Polyomavirus Transforming; Calcium; Calcium Channel Agonists; Calcium Channels; Calcium Channels, L-Type; Dose-Response Relationship, Drug; Glyburide; Insulin; Insulin Secretion; Insulinoma; Kinetics; Mice; Mice, Transgenic; Pancreatic Neoplasms; Promoter Regions, Genetic; Pyrroles; Simian virus 40; Tumor Cells, Cultured	1997
Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer research, 2000, Jun-01, Volume: 60, Issue:11 Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Deoxycytidine; Down-Regulation; Endothelium; ErbB Receptors; Fluorescent Antibody Technique; Gemcitabine; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Signal Transduction; Time Factors; Tumor Cells, Cultured	2000
Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. Proceedings of the National Academy of Sciences of the United States of America, 2000, Aug-01, Volume: 97, Issue:16 Topics: Animals; Antibiotics, Antineoplastic; Cadherins; Cell Division; Cricetinae; Cytotoxins; Doxorubicin; Fungal Proteins; GTPase-Activating Proteins; Intracellular Signaling Peptides and Proteins; Male; Mesocricetus; Neoplasm Metastasis; Pancreatic Neoplasms; Phosphorylation; Protein Phosphatase 1; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Protein Tyrosine Phosphatases; Pyrroles; Saccharomyces cerevisiae Proteins; Tumor Cells, Cultured; Tyrosine	2000
Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:8 Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Division; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Endothelial Growth Factors; Enzyme Inhibitors; ErbB Receptors; Gemcitabine; Humans; Immunohistochemistry; Interleukin-8; Lymphokines; Male; Mice; Mice, Nude; Neoplasm Metastasis; Pancreatic Neoplasms; Phosphorylation; Platelet Endothelial Cell Adhesion Molecule-1; Proliferating Cell Nuclear Antigen; Pyrimidines; Pyrroles; Ribonucleotide Reductases; Signal Transduction; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Xenograft Model Antitumor Assays	2001
Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:9 Topics: Animals; Antibiotics, Antineoplastic; Binding, Competitive; Cell Division; Doxorubicin; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Neoplasms, Experimental; Pancreatic Neoplasms; Pyrroles; Receptors, Somatostatin; RNA, Messenger; Survival Analysis; Time Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2001
Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer research, 2002, Mar-15, Volume: 62, Issue:6 Topics: Animals; Cell Division; Chemotherapy, Adjuvant; Female; Fibrosarcoma; Humans; Indoles; Mammary Neoplasms, Experimental; Mice; Mice, Inbred A; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Nude; Oxindoles; Pancreatic Neoplasms; Propionates; Pyrroles; Radiation-Sensitizing Agents; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor	2002
Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer research, 2002, Apr-01, Volume: 62, Issue:7 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Deoxycytidine; Endothelium, Vascular; ErbB Receptors; Gemcitabine; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Phthalazines; Pyridines; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Xenograft Model Antitumor Assays	2002